The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?

The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?
The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?
CME, CPE
Shaji K. Kumar, MD
Release Date: April 01, 2021
Expiration Date: April 01, 2022

There has been an increasing interest in the potential for moving beyond three-drug combinations to improve the treatment of patients with multiple myeloma in the frontline setting. In this activity, Dr. Kumar discusses the rationale, decision making, and trials that explore four-drug combinations for patients with newly diagnosed multiple myeloma. He also explains the efficacy and toxicity burden of these regimens.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
Begin, Earn CreditView Only, No CreditGet Certificate